(MENAFN Editorial) STARTRK-2clinical trial sites in Asia working with Ignyta, Inc., (NASDAQ: RXDX), a biotechnology company focused on precision medicine inoncology. Angsana Molecular & Diagnostics' RNA-based fusions cancerpanel will be used for screening TRK, ROS1 and ALK fusions in the STARTRK-2 clinical trial, a registration-enabling global Phase 2 basket clinical trial forentrectinib, Ignyta's investigational, orally available, CNS-active tyrosinekinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions.
Phase 1 data recently published online in Cancer Discovery showed entrectinib tobe well tolerated, with responses observed in non-small cell lung cancer(NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanomaand renal cell carcinoma as early as four weeks after first treatment andlasting as long as 2.5 years and still ongoing. Thatpublication reported a 79% response rate in 24 patients with TRK, ROS1, orALK-driven extracranial solid tumors, and showed entrectinib responses to beboth rapid and durable in patients with advanced solid tumors across multiplehistologies and each of the molecular targets of interest, including inmultiple patients with metastatic CNS disease.
"Ignyta is excited to partner with Angsana toconduct diagnostic screening at our STARTRK-2 clinical trial sites in Asia,which will help us get entrectinib to patients with tumors driven by TRK, ROS1or ALK fusions," said Jonathan Lim, M.D., Chairman and CEO of Ignyta."Entrectinib is the only TRK inhibitor to have published datademonstrating RECIST responses in NSCLC and in patients with cancer in the CNS.The anti-tumor activity seen across cancer types and entrectinib's ability totreat bulky CNS disease, particularly important given the propensity for manysolid tumors to metastasize to the brain, is extremely encouraging," continuedDr. Lim.
"The era of the shift away fromone-size-fits-all, trial-and-error medicine, toward a health care system thatutilizes molecular information to improve outcomes and make the health caresystem more efficient, has finally arrived to Asia Pacific especially in thearea of targeted therapy for oncology,"says Dr. Chris Tan, ChiefEcutive Officer and founder ofAngsana Molecular & Diagnostics.Dr. Chris Tan added that our College of American Pathologists (CAP) accreditedmolecular laboratories in #Singapore and Hong Kong, turnaround time and costefficiency are critical to support Ignyta for their STARTRK-2 trial inSingapore and Asia.
About Angsana Molecular & DiagnosticsLaboratory AngsanaMolecular & Diagnostics Laboratory specializes in developing premiummolecular diagnostic assays, serving the following four medical areas that havethe largest impact in Asian population: allergy and molecular allergology,fetal maternal health, molecular oncology and pharmacogenetics. Throughanalysis of medical conditions at a molecular level, combined with clinicalconsultation by board-certified medical geneticists and sub-specialty trainedpathologists, Angsana empowers clinicians and patients to make better informedclinical decisions and improve the quality of patient care. Strategicallylocated in the center of Asia with multi-laboratory CAP accredited operationsin #Singapore
and Hong Kong. Angsana Molecular & Diagnostics Laboratory isdedicated to serving the Asian community with fast and more affordable serviceswithin easy reach. For more information, visit www.angsanadx.com.
Blazing a New Future for Patients with Cancer™
At Ignyta, we work tirelessly on behalf ofpatients with cancer to offer potentially life-saving, precisely targetedtherapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integratedRx/Dx strategy allows us to enter uncharted territory, illuminating themolecular drivers of cancer and quickly advancing treatments to address them.This approach embraces even those patients with the rarest cancers, who havethe highest unmet need and who may otherwise not have access to effectivetreatment options. With our pipeline of potentially first-in-class orbest-in-class precision medicines, we are pursuing the ultimate goal of notjust shrinking tumors, but eradicating cancer relapse and recurrence inprecisely defined patient populations.
For more information, please visit:www.ignyta.com.